Metamizol Gemax Pharma

Metamizole sodium, the active ingredient in Metamizol Gemax Pharma, is a pyrazolone presented as an oral formulation for oral use. It is used to relieve pain, reduce fever, and treat colic in adult patients. GNH USA supplies Metamizol Gemax Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Gemax Pharma is indicated for conditions involving acute or severe pain, fever, and gastrointestinal colic. - Pain: provides analgesic relief for moderate to severe acute pain. - Fever: reduces elevated body temperature in febrile states. - Colic: alleviates painful intestinal or biliary colic episodes.

Metamizol Gemax Pharma may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Hypotension: occasional drop in blood pressure. - Rash: skin redness or itching. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Anaphylactic reaction: life‑threatening allergy. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: liver injury indicated by elevated enzymes.

Before prescribing Metamizol Gemax Pharma, clinicians should consider several safety measures. - Renal function: assess kidney status in patients with impairment. - Hematologic monitoring: perform baseline and periodic blood counts. - Allergy history: avoid in individuals with known hypersensitivity to pyrazolones. - Concomitant myelosuppressants: use caution when combined with other bone‑marrow‑suppressing agents. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metamizol Gemax Pharma can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other pyrazolones: increased risk of severe blood dyscrasias. - Anticoagulants: potential enhancement of bleeding tendency. - Immunosuppressants: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened gastrointestinal irritation. - CYP450 substrates: possible alteration of metabolic clearance. - Alcohol: may intensify hypotensive effects.